Record ANDAs don’t solve all problems

Arecord number of final and tentative abbreviated new drug application (ANDA) approvals by the US Food and Drug Administration (FDA) in the agency’s fiscal year ended 30 September 2018 is welcome, but only goes part way to alleviating the pressures being exerted on the US generics industry, according to theAssociation for Accessible Medicines (AAM).